A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod

Background Fingolimod is the first oral disease-modifying therapy indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses and delay the progression of physical disability caused by MS.